drugset / Trial / NCT00386685
XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of the study is to assess the activity of XRP9881 in combination with trastuzumab. The secondary objectives are safety and pharmacokinetic interaction
Timeline
- Start
- 2006-07
- Primary completion
- 2008-10
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | larotaxel | Small molecule | — | Intravenous |
| Background | Trastuzumab | Monoclonal antibody | — | Intravenous |